S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
common stock · Exchange Nasdaq
2026-11-19 · 0001477932-26-007188
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
common stock · Exchange NASDAQ
2026-11-17 · 0001477932-26-007117
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
Exchange NASDAQ
2026-11-05 · 0001477932-26-006714
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
Common Stock · Exchange Nasdaq
2026-10-29 · 0001477932-26-006517
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
common stock · Exchange NASDAQ
2026-10-15 · 0001477932-26-006268
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common Stock · Exchange Nasdaq · Selling stockholders only · Use of proceeds Proceeds will be distributed to selling stockholders with no direct proceeds to the company
2026-09-25 · 0001477932-26-005809
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-06-11 · 0001477932-26-003813
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-05-12 · 0001477932-26-002999
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-04-17 · 0001477932-26-002370
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-03-27 · 0001477932-26-001630
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2026-02-06 · 0001477932-26-000677
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
Begins the tracked draft filing sequence after RW.
MED-X's current DRS is an offering-focused update that shifts the company's visible financing path from a prior S-1/A IPO process to a Regulation A offering. The filing updates financial discussion through the six months ended June 30, 2025, showing modest revenue growth to $885,520 but continued material net losses of $4,135,351. It discloses that the prior SEC IPO pursuit was terminated in April 2024 and that a Regulation A offering of up to 2,500,000 shares at $4.00 per share, or up to $10,000,000 in gross proceeds, received Notice of Qualification on May 29, 2025. Recent developments also include a 1-for-16 reverse stock split, board changes, completed Reg CF/Reg D offerings, and new engagement of Dealmaker Securities as lead selling agent.
2026-01-28 · 0001477932-26-000474
RW
withdrawn
Withdrawal request
Issuer requested withdrawal of the registration statement.
Follows S-1/A and ends the active registration process.
2024-04-23 · 0001477932-24-002292
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · Range $4.00 to $6.00 · 1,150,000 shares
warrant to purchase one share · Exchange Nasdaq · Over-allotment 172,500 · Each Unit consists of one share of common stock and one warrant to purchase one share of common stock · Warrants to purchase 1,150,000 shares of common stock exercisable at 100% of the initial public offering price for five years · Use of proceeds To fund the acquisition of Napco Painting Contractors, Inc. and for general corporate purposes · Flags units, warrants · Underwriters Maxim Group LLC
This S-1/A amendment updates the prospectus with capitalization and MD&A information through September 30, 2023. The offering is now described using Units at an assumed $5.00 per Unit, rather than shares at $5.00 per share in the prior filing, and the capitalization sensitivity has been restated per 100,000 Units. Common shares outstanding increased to 3,443,770, pro forma total capitalization is shown at $9,909,900, and the company continues to report limited revenue, recurring losses, low cash balances, customer concentration, and cannabis-related regulatory uncertainty.
2024-02-09 · 0001477932-24-000633
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · Range $4.00 to $6.00 · 1,150,000 shares · Gross proceeds $5,750,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 172,500 · Warrants to purchase up to 5% of shares sold in offering (3% for shares introduced by Company) · Use of proceeds To fund the acquisition of Napco Painting Contractors, Inc. · Flags warrants · Underwriters Maxim Group LLC
2023-10-27 · 0001477932-23-007926
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $5.00 · Range $4.00 to $6.00 · 1,150,000 shares · Gross proceeds $5,750,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 172,500 · Warrants to purchase up to 5% of shares sold · Use of proceeds debt repayment, working capital, acquisitions · Flags warrants · Underwriters Maxim Group LLC
MED-X, Inc. is preparing for its IPO with an assumed public offering price of $5.00 per share, focusing on its natural product lines (Nature-Cide, Thermal-Aid, Malibu Brands) and Cannabis-related ventures. The filing outlines capitalization details, including shares to be issued to the CEO, a consultant, and note conversions. Financials show declining revenue and increasing losses, with operational expenses outpacing revenue. The company highlights e-commerce growth but faces risks related to customer concentration, profitability, and legal uncertainties around Cannabis operations.
2023-10-03 · 0001477932-23-007319
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.00 · 2,125,000 shares · Gross proceeds $8,500,000
Common Stock, par value $0.001 per share · Exchange Nasdaq · Ticker MXRX · Over-allotment 318,750 · Use of proceeds debt repayment, working capital, acquisitions · Underwriters R.F. Lafferty & Co., Inc.
MED-X, Inc. is seeking to go public with an IPO on Nasdaq, aiming to raise capital through the sale of 2,125,000 shares at $4.00 per share. The company operates in product development, distribution, and marketing of natural branded products including Nature-Cide, Thermal-Aid, and Malibu Brands, alongside a media platform (MJT Network) focused on Cannabis content. Financials show revenue growth but increasing operating losses, with significant expenses tied to expansion, marketing, and compliance. The filing highlights risks of dilution from share issuances, dependence on key customers, and uncertainties around Cannabis-related operations due to regulatory constraints.
2023-06-07 · 0001477932-23-004277
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.00 · 2,125,000 shares · Gross proceeds $8,500,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 318,750 · Use of proceeds for working capital and general corporate purposes · Underwriters R.F. Lafferty & Co., Inc.
Med-X, Inc. is a Nevada-based company engaged in developing, distributing, and marketing natural products under brands like Nature-Cide, Thermal-Aid, and Malibu Brands. The company also operates the MJT Network, a cannabis-focused media platform. Following a 2018 merger with PSH, Med-X has expanded its product lines, including cannabis-related offerings. Financially, revenue grew to $1.85M in 2022, driven by Nature-Cide and Thermal-Aid, while operational expenses surged, leading to a net loss of $7.34M. The company seeks additional capital through equity offerings to sustain operations, with plans to explore cannabis cultivation and compound extraction as regulations evolve.
2023-05-15 · 0001477932-23-003546
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.00 · 2,125,000 shares · Gross proceeds $8,500,000
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 318,750 · Use of proceeds Proceeds to Med-X, Inc. · Underwriters EF Hutton, division of Benchmark Investments, LLC, CRAFT CAPITAL MANAGEMENT, LLC
MED-X, Inc. operates in the cannabis and wellness sectors through branded products like Nature-Cide, Thermal-Aid, and Malibu Brands, along with a media platform (MJT Network). The company generates revenue from product sales (primarily Nature-Cide and Thermal-Aid) and digital advertising. Despite revenue growth, it reports significant operating losses, relies heavily on a few customers, and faces liquidity challenges requiring additional capital. The filing highlights expansion into cannabis agricultural markets and ongoing financial risks.
2022-10-26 · 0001477932-22-007917
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Price $4.15 · Range $4.00 to $4.30 · 1,686,747 shares
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 253,012 · Use of proceeds working capital · Underwriters EF Hutton, division of Benchmark Investments, LLC
MED-X, Inc. operates in the cannabis and health sectors, offering all-natural products under brands like Nature-Cide® and Thermal-Aid®, targeting pest control, agriculture, and pain relief. The company also manages the MJT Network, a media platform generating ad revenue. Revenue primarily comes from Nature-Cide (54.5% in 2022) and Thermal-Aid (33.4%), with Malibu Brands and MJT Network contributing minimally. Despite revenue growth, the company reports significant net losses, relying on capital raises to sustain operations. It seeks to expand into cannabis agriculture and faces challenges including customer concentration, regulatory risks, and liquidity constraints.
2022-09-23 · 0001477932-22-007157
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
Price $4.15 · Range $4.00 to $4.30 · 1,686,747 shares
Common Stock · Exchange Nasdaq · Ticker MXRX · Over-allotment 262,500 · Underwriters EF Hutton, division of Benchmark Investments, LLC
MED-X, Inc. operates in the cannabis and wellness sectors, offering all-natural products under brands like Nature-Cide, Thermal-Aid, and Malibu Brands. The company generates revenue through product sales via e-commerce, distributors, and the MJT Network media platform. Despite revenue growth, the company reports significant operating losses and relies on capital raises to sustain operations. Key revenue drivers are Nature-Cide (54.5%) and Thermal-Aid (33.4%), with Malibu Brands and MJT Network contributing minimally. The company faces challenges including dependence on key customers, ongoing losses, and the need for additional capital.
2022-09-19 · 0001477932-22-007030
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Price $4.15 · 1,556,265 shares
Share of Common Stock and One Warrant to Purchase One Share · Exchange Nasdaq · Ticker MXRX · Over-allotment 233,440 · One Share of Common Stock and One Warrant to Purchase One Share of Common Stock · Warrants to purchase one share of common stock at $4.15, expiring five years from issuance · Flags units, warrants · Underwriters EF Hutton, division of Benchmark Investments, LLC
MED-X, Inc. operates through three brands: Nature-Cide® (all-natural pesticides), Thermal-Aid® (pain relief products), and Malibu Brands (essential oils). The company generates revenue from product sales via e-commerce, distributors, and the MJT Network media platform. Despite revenue growth, the company reports significant operating losses and relies on capital raises to sustain operations. It targets the cannabis industry with specialized products and faces risks related to profitability, customer concentration, and regulatory environments.
2022-09-08 · 0001477932-22-006725
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
MED-X, Inc. disclosed a restatement of its 2020 financial statements due to errors in classifying production costs and labor expenses. The adjustments impacted inventory, cost of goods sold, and operating expenses, with a net increase to retained earnings. The company also noted that ASU 2020-06, effective 2024, would not materially affect its financials. Lease obligations and related party transactions were disclosed, including a land lease from an executive and legal services from a shareholder.
2022-08-04 · 0001477932-22-005646
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
MED-X, Inc. filed a DRS/A on 2022-07-21, disclosing financial restatements for fiscal 2020 due to errors in production cost allocations and labor expense categorization. The company adjusted retained earnings, inventory, COGS, and operating expenses. It also addressed accounting standard ASU 2020-06, noting no material impact. The filing includes detailed segment disclosures, revenue breakdowns by product and channel, and lease obligations with $1.1M in lease liabilities. Related party transactions and supplier concentration risks are highlighted.
2022-07-21 · 0001477932-22-005277
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
MED-X, Inc. filed a DRS/A on 2022-06-21, disclosing financial restatements, operational segments, and risk factors. The company corrected prior period errors in production costs and labor expenses, adjusting retained earnings and inventory. It operates through three product brands (Nature-Cide, Thermal-Aid, Malibu Brands) and an online media platform. The filing highlights lease obligations, supplier concentration, and related party transactions. No material impact from ASU 2020-06 accounting standards was anticipated.
2022-06-21 · 0001477932-22-004538
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
MED-X, Inc. filed a DRS/A on 2022-05-06, disclosing financial restatements for 2020, adjustments to inventory, cost of goods sold, and operating expenses. The company operates in three product segments (Nature-Cide, Thermal-Aid, Malibu Brands) with revenue primarily from e-commerce and distributors. Key financial highlights include a $1.01M total revenue in 2021, $332,971 in rent expenses, and a $1.15M lease liability. The filing also details related party transactions, supplier concentration risks, and a $736 annual imputed rent from an executive.
2022-05-06 · 0001477932-22-003014
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
MED-X, Inc. is conducting an IPO with a proposed 1-for-8 reverse stock split, aiming to list on Nasdaq under the symbol 'MXRX'. The offering is underwritten by EF Hutton, division of Benchmark Investments, LLC, with lock-up agreements for officers and directors. The company outlines indemnification policies for directors/officers and details restrictions on future share sales, including Rule 144 and Rule 701 compliance. A warrant component is included for the underwriters, with specific registration rights and anti-dilution provisions.
2022-02-10 · 0001477932-22-000653